OMEICOS Therapeutics is developing a novell molecule utilizing a new Mode of Action for the treatment and prevention of atrial fibrillation.
OMEICOS has raised €17M across 1 funding round from 3 investors, most recently a Series C round in Oct 2018. Based in Berlin, Germany; founded 2013; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2018-10-01 | Series C | €17M |
| Forbion Capital Partners,SICAR,Vesalius Biocapital Partners |
| View deal → |
